Kelun-Biotech

The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine

PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65;…